Web of Science: 7 citations, Scopus: 8 citations, Google Scholar: citations,
Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
Ruiz de Porras, V. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bystrup, Sara (Institut Germans Trias i Pujol)
Cabrero de las Heras, Sara (Institut Germans Trias i Pujol)
Musulén, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Palomero, L. (Institut d'Investigació Biomèdica de Bellvitge)
Alonso, M.H. (Universitat de Barcelona. Departament de Ciències Clíniques)
Nieto Raya, Rocio (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Arango, Diego (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Moreno, V. (Universitat de Barcelona. Departament de Ciències Clíniques)
Queralt, C. (Institut Germans Trias i Pujol)
Manzano Mozo, José Luís (Institut Germans Trias i Pujol)
Layos, Laura (Institut Germans Trias i Pujol)
Bugés, Cristina (Institut Germans Trias i Pujol)
Martínez Balibrea, Eva (Institut Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date: 2019
Abstract: In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Grants: Instituto de Salud Carlos III PI09-01334
Instituto de Salud Carlos III PI12-02228
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-1494
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-1705
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-723
Instituto de Salud Carlos III PIE16-00011
Instituto de Salud Carlos III PI16-00540
Instituto de Salud Carlos III AC15-00066
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Colorectal cancer ; Cyclin-dependent kinase 5 (Cdk5) ; Oxaliplatin ; Prognostic and predictive biomarker
Published in: Cancers, Vol. 11 Núm. 10 (october 2019) , p. 1540, ISSN 2072-6694

DOI: 10.3390/cancers11101540
PMID: 31614664


17 p, 2.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles

 Record created 2020-06-03, last modified 2022-05-18



   Favorit i Compartir